Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;10(12):6388-6391.
doi: 10.21037/jtd.2018.11.22.

Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial

Umberto Malapelle  1 , Luis E Raez  2 , Maria Jose Serrano  3   4 , Christian Rolfo  5 ; International Society of Liquid Biopsies (ISLB)
Affiliations
Editorial

Detection of epidermal growth factor receptor mutations in circulating tumor DNA: reviewing BENEFIT clinical trial

Umberto Malapelle et al. J Thorac Dis. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Graphical representation of main molecular biology techniques used in the reported studies. In the left panel was represented wild-type (green) and mutated (red) RT-PCR amplification curves. In the center was reported an example of digital PCR compartmentalization with wild-type (green) and mutated (red) separated alleles. In the right panel was reported a schematization of NGS sequences (reads) pil-up for a visual inspection of mutated (read “T”) alleles. rfu, relative fluorescence unit; c, cycles; RT-PCR, real-time polymerase chain reaction; NGS, next generation sequencing.
See this image and copyright information in PMC

Comment on

References

    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46. 10.1016/S1470-2045(11)70393-X - DOI - PubMed
    1. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51. 10.1016/S1470-2045(14)71173-8 - DOI - PubMed
    1. Malapelle U, Bellevicine C, De Luca C, et al. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer Cytopathol 2013;121:552-60. 10.1002/cncy.21322 - DOI - PubMed